Supernus Pharmaceuticals Return on Investment 2011-2024 | SUPN

Current and historical return on investment (ROI) values for Supernus Pharmaceuticals (SUPN) over the last 10 years.
Supernus Pharmaceuticals ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2024-09-30 $0.06B inf%
2024-06-30 $0.03B inf%
2024-03-31 $-0.01B inf%
2023-12-31 $-0.01B inf%
2023-09-30 $0.03B inf%
2023-06-30 $0.02B inf%
2023-03-31 $0.05B inf%
2022-12-31 $0.05B 14.65%
2022-09-30 $0.02B 2.81%
2022-06-30 $0.05B 5.76%
2022-03-31 $0.08B $1.23B 6.30%
2021-12-31 $0.09B $1.20B 7.39%
2021-09-30 $0.12B $1.19B 10.77%
2021-06-30 $0.15B $1.16B 13.07%
2021-03-31 $0.16B $1.12B 14.53%
2020-12-31 $0.17B $1.11B 16.60%
2020-09-30 $0.17B $1.09B 17.08%
2020-06-30 $0.16B $1.04B 16.25%
2020-03-31 $0.15B $0.96B 16.71%
2019-12-31 $0.15B $0.94B 16.97%
2019-09-30 $0.15B $0.90B 17.66%
2019-06-30 $0.15B $0.86B 18.11%
2019-03-31 $0.14B $0.81B 18.07%
2018-12-31 $0.14B $0.78B 19.78%
2018-09-30 $0.14B $0.75B 25.92%
2018-06-30 $0.12B $0.71B 35.60%
2018-03-31 $0.11B $0.67B 50.17%
2017-12-31 $0.10B 90.00%
2017-09-30 $0.08B 50.94%
2017-06-30 $0.08B $0.23B 38.77%
2017-03-31 $0.07B $0.21B 37.14%
2016-12-31 $0.05B $0.20B 36.36%
2016-09-30 $0.05B $0.18B 37.32%
2016-06-30 $0.03B $0.12B 30.92%
2016-03-31 $0.02B $0.10B 25.21%
2015-12-31 $0.02B $0.10B 24.93%
2015-09-30 $0.02B $0.09B 23.30%
2015-06-30 $0.01B $0.08B 16.90%
2015-03-31 $0.01B $0.08B 18.05%
2014-12-31 $-0.00B $0.07B -8.06%
2014-09-30 $-0.02B $0.06B -33.73%
2014-06-30 $-0.04B $0.06B -56.92%
2014-03-31 $-0.06B $0.06B -76.45%
2013-12-31 $-0.06B $0.07B -85.61%
2013-09-30 $-0.06B $0.07B -88.11%
2013-06-30 $-0.06B $0.10B -92.06%
2013-03-31 $-0.05B $0.05B -98.11%
2012-12-31 $-0.04B $0.07B -91.80%
2012-09-30 $-0.04B $0.04B -106.85%
2012-06-30 $-0.04B $0.06B -138.32%
2012-03-31 $-0.04B $0.02B -276.92%
2011-12-31 $-0.04B $0.03B -462.50%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00